AMRX — Amneal Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $3.07bn
- $5.76bn
- $2.39bn
- 75
- 62
- 99
- 93
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,626 | 1,993 | 2,094 | 2,212 | 2,394 |
Cost of Revenue | |||||
Gross Profit | 479 | 663 | 792 | 796 | 857 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,675 | 1,901 | 1,941 | 2,307 | 2,189 |
Operating Profit | -48.5 | 91.3 | 153 | -94.9 | 204 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -220 | -35.8 | 31.4 | -248 | -40.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -604 | -41.4 | 20.2 | -255 | -48.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -362 | 91.1 | 10.6 | -130 | -84 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -362 | 91.1 | 10.6 | -130 | -84 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.44 | 0.109 | 0.339 | 0.406 | -0.217 |